SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Here's What Happened

Key Points

• SELLAS shares dropped at the open, falling from a prior close of $15.21 to $14.77 and last trading at $14.38 on volume of roughly 1.18 million shares.
• Analyst sentiment remains mixed: two analysts rate the stock a Buy and one rates it a Sell, resulting in a consensus rating of Hold and an average price target of $10.00.
• The company reported quarterly EPS of -$0.05, missing estimates by $0.01, while institutional investors and hedge funds collectively own 17.38% of its shares.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $15.21, but opened at $14.77. SELLAS Life Sciences Group shares last traded at $14.38, with a volume of 1,176,568 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on SLS shares. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The firm's fifty day simple moving average is $12.37 and its 200 day simple moving average is $8.05. The stock has a market capitalization of $2.78 billion, a P/E ratio of -65.52 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Hedge Funds Weigh In On SELLAS Life Sciences Group

Institutional investors have recently modified their holdings of the business. Nykredit A S acquired a new stake in SELLAS Life Sciences Group in the second quarter valued at about $27,000. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth about $26,000. California State Teachers Retirement System boosted its stake in shares of SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after purchasing an additional 1,709 shares in the last quarter. Beacon Pointe Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group during the 4th quarter valued at approximately $38,000. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group during the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 17.38% of the company's stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source